Reig Jofre commits to vertical integration in the production of biotechnological medicines with an investment of eur 5.8m in Leanbio
- REIG JOFRE strengthens its presence in the biotechnology sector by consolidating itself as a strategic partner of Leanbio, reinforcing its position in vertical integration of the development of recombinant proteins, antibodies, and advanced therapies.
- REIG JOFRE evolves from the fill & finish process of finished pharmaceutical products towards complete vertical integration in the development, characterization, and production
of biotechnological active ingredients. This advance enables the provision of integrated services in biologics, mRNA, and advanced therapies, supported by its expertise in cuttingedge technology for the development of high value injectables.
REIG JOFRE, (BME:RJF), a pharmaceutical company born with the firm conviction of universalizing health, announces an investment of 5.8 million euros in the biotechnology company Leanbio. This investment aims to achieve vertical integration in the development, characterization, and production of biotechnological active ingredients. REIG JOFRE leverages its existing facilities and know-how in formulation, stabilization, characterization, and industrial scaling, as well as aseptic production of finished pharmaceutical products, through this investment.
REIG JOFRE transitions from the pharmaceutical fill & finish process to vertical integration in the production of innovative biotechnological and biosimilar products. This advance is facilitated through collaboration with Leanbio, in which REIG JOFRE has held a 10% stake to date. The operation, funded through a combination of capital and debt, has been spearheaded by REIG JOFRE in conjunction with other Leanbio partners. As a result, REIG JOFRE will increase its stake in Leanbio to reach 24%, committing to further increase its presence as the expansion plan progresses.